Emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate - Generic Drug Details

What are the generic drug sources for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate and what is the scope of freedom to operate?

Emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate is the generic ingredient in two branded drugs marketed by Gilead Sciences Inc, Laurus, and Mylan, and is included in three NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate has fifty-five patent family members in thirty-seven countries.

Three suppliers are listed for this compound.

Summary for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

International Patents:	55
US Patents:	1
Tradenames:	2
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	3
Clinical Trials:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
DailyMed Link:	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate at DailyMed

Recent Clinical Trials for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Pharmaceutical K.K.	Phase 4
Azienda Ospedaliera San Gerardo di Monza	Phase 4
Gilead Sciences	Phase 4

See all emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate clinical trials

Pharmacology for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AG	Non-nucleoside reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COMPLERA	Tablets	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	200 mg/25 mg/ 300 mg	202123	1	2015-05-20

US Patents and Regulatory Information for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	208452-001	May 20, 2025	AB	RX	No	No
Laurus	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	220232-001	Mar 4, 2026	AB	RX	No	No
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	AB	RX	Yes	Yes	10,857,102		Y

Expired US Patents for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,716,264
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	7,125,879
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	6,838,464
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,592,397
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,101,629

International Patents for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Country	Patent Number	Title	Estimated Expiration
Philippines	12013501002	THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Malaysia	185604	THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Peru	20170521	COMBINACION FARMACEUTICA QUE COMPRENDE RILPIVIRINA HCL, TENOFOVIR DISOPROXIL FUMARATO Y EMTRICITABINA
Singapore	190333	THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Canada	2818097

Supplementary Protection Certificates for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0513200	122004000015	Germany		PRODUCT NAME: EMTRIVA-EMTRICITABINE; REGISTRATION NO/DATE: EU/1/03/261/001-003 20031024
0915894	05C0032	France		PRODUCT NAME: TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE; REGISTRATION NO/DATE: EU/1/04/305/001 20050221
3808743	LUC00275	Luxembourg		PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU D'UNE FORME THERAPEUTIQUEMENT EQUIVALENTE DE CELLE-CI PROTEGEE PAR LE BREVET DE BASE, TELLE QU'UN SEL D'ADDITION PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE, ET D'EMTRICITABINE; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001-002 20111128
1663240	1690062-3	Sweden		PRODUCT NAME: A COMBINATION OF: RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE; EMTRICITABINE; AND TENOFOVIR ALAFENAMIDE, OR A PHARMCEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TENOFOVIR ALAFENAMIDE FUMARATE.; REG. NO/DATE: EU/1/16/1112 20160623
1663240	300851	Netherlands		PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623

Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What product line is in scope?

The fixed-dose combination (FDC) is marketed as complera (single-tablet regimen) in multiple geographies and is commonly referenced in filings and market databases as emtricitabine + rilpivirine hydrochloride + tenofovir disoproxil fumarate.

Core regimen attributes that shape demand

• Indication: HIV-1 infection (antiretroviral therapy; regimen-level usage depends on label language per region).
• Dosing form: oral, fixed-dose tablet (one-tablet regimen).
• Therapeutic class mix: nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone (emtricitabine, tenofovir disoproxil fumarate) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) (rilpivirine).
• Switch dynamics: patients frequently move between FDCs and to newer regimens (including once-daily integrase inhibitor based options), with tenure historically driven by tolerability, simplicity, and price.

How has the HIV ART market shaped pricing power?

The HIV market’s structure has compressed price over time through:

• Class turnover: integrase strand transfer inhibitor (INSTI) based backbones displaced earlier NNRTI-based regimens in many markets where payer formularies and guideline sequences shifted.
• Exclusivity erosion: FDCs with older components face faster competitive pressure once NRTI/NNRTI generics enter; even where the exact triple FDC remains protected in a given market, component-level generic competition and regimen switching reduce willingness to pay.
• Formulary steering: national and payer formularies increasingly prefer regimens with broad guideline acceptance and simplified monitoring.

Implication for this FDC

• The regimen’s value proposition rests on regimen convenience for stable patients and “keep on therapy” economics. When payer behavior shifts toward newer backbones, the addressable segment narrows to existing users rather than net-new starts.

What is the competitive set that drives share migration?

Competitive pressure typically comes from two channels:

1) Direct FDC and near-FDC competitors

• Other NRTI- or NNRTI-based fixed-dose regimens in the same line of therapy.
• Competing FDCs built on alternative NNRTI backbones or different NRTI pairs.

2) Dominant modern “preferred” regimens

• INSTI-based one-tablet regimens that have moved into first-line and much of second-line usage in many guidelines and payer systems.
• These regimens often show better resistance profiles and fewer switching triggers, which increases uptake when formularies update.

Net effect: This triple FDC’s growth typically tracks patient retention and switch-in from older NNRTI users, offset by net switches out toward INSTI based therapies.

How do IP and generic entry dynamics affect revenue trajectory?

This product’s financial trajectory is structurally linked to:

• Patent expiry for components and combinations across major markets.
• Generic availability of emtricitabine, tenofovir disoproxil fumarate, and rilpivirine (and of alternative FDC compositions).
• Market-specific exclusivity details and launch timing of generic equivalents.

While specific filing-by-filing status varies by country, the direction of impact is consistent across mature HIV franchises:

• After generic penetration, pricing declines and volumes remain more resilient than price, often leading to a revenue flattening-to-decline profile.
• FDC “brand premium” erodes as prescribers switch to generics for new patients and payers for stable patients.

Bottom line for financial trajectory

• Expect a late-life brand pattern: peak years driven by adoption, followed by gradual revenue erosion once generics and preferred-regimen switches dominate.

What market dynamics determine near-term demand?

Key demand drivers for this FDC in the near term:

• Patient base aging on therapy: stable patients remain on a tolerable regimen unless clinically driven to switch.
• Guideline/payer preference for INSTI-based regimens: reduces new starts in regions where formularies have updated.
• Switch triggers and adherence economics: if the regimen is already established, switching may be deferred, which can moderate declines.

How does resistance management influence switching rates?

The regimen’s continued use depends on resistance patterns and patient history:

• NNRTI-based regimens can face higher switching frequency when prior NNRTI exposure exists or resistance mutations accumulate.
• In practice, clinics tend to switch toward INSTI regimens when resistance or treatment history raises clinical risk.

This creates a feedback loop:

• More switches out reduce marginal demand for the brand FDC.
• Reduced new starts accelerate long-term share erosion.

What financial trajectory should investors underwrite?

In mature ART, financial outcomes usually separate into three phases:

1. Adoption phase: volume growth as guidelines adopt and prescribers switch.
2. Late-life stability: revenue stabilizes as a persistent stable-patient cohort remains.
3. Downtrend: revenue declines as generics and newer preferred regimens take new starts and drive switches.

For this specific triple FDC, the most likely trajectory is phase 2 turning into phase 3 as:

• modern preferred regimens dominate new prescribing,
• generic and alternative regimens compress net price.

Evidence anchors you should align with in diligence

Use these as your “proof points” when mapping to actual revenue lines and market share:

• Company segment reporting: HIV franchise and major product line items in annual reports.
• Claims data / prescriptions: prescription trends in US and EU5 markets, where available.
• Patent and exclusivity calendars: brand vs generic availability by market.
• Tender and payer contracts: reimbursement rates and formulary status changes.

How does regional policy change revenue risk?

Revenue risk differs by region:

• US and peer high-income markets: payer formularies and Medicare/managed Medicaid dynamics can shift prescribing quickly to preferred regimens. Generic penetration for components typically compresses price.
• EU markets: parallel trade and tender-based reimbursement accelerate erosion once generics or therapeutic alternatives gain contracting status.
• High-burden markets: procurement tends to track cost and supply reliability. In those settings, older branded regimens frequently lose to low-cost generic procurement, unless protected by market-specific contract structures.

What is the product’s investment profile as a late-life asset?

From a business and investment standpoint, the asset behaves like a mature franchise line item:

• Upside is constrained to retention and slower-than-expected switching.
• Downside is driven by contract pricing, generic share, and continued guideline migration toward INSTI regimens.
• Cash flow quality depends on brand premium remaining longer than expected and on whether clinics keep stable patients on the regimen.

What operational factors influence the trajectory further?

• Supply chain continuity for stable patient cohorts (avoid stockouts that trigger switching).
• Market access discipline: maintaining formulary position for stable patients can delay revenue erosion.
• Competitive response speed: if competing products add marketing access or preferred-tier positioning quickly, share declines faster.

How does this regimen compare versus other HIV FDCs?

This FDC’s relative performance typically differs from newer “best-in-class” one-tablet regimens:

• It sits in a lower-preference lane as INSTI-based options dominate guideline sequences.
• It faces component generic competition and regimen-level switching, which reduces incremental growth.
• Its revenue tends to be more dependent on existing user retention than on net-new uptake.

Market snapshot framework (what to measure, and what to expect)

Even without inserting speculative numbers, you can map expected financial behavior to measurable indicators:

Variable	What to measure	Expected direction for this FDC
Net price	Wholesale acquisition cost, contract price trends	Down after generic and preferred-regimen pressure
Prescription volumes	New starts vs continuation prescriptions	Continuation may hold longer than new starts
Formulary status	Preferred vs non-preferred tier changes	Downshift risk as payers prefer INSTI regimens
Generic competition	Timeline of generic launches and FDC availability	Accelerates erosion after entry
Switching rate	Clinical and claims-based treatment changes	Moves toward INSTI-based regimens

What are the most decision-relevant scenarios?

Scenario A: Retention outperforms

• Continuation cohort stays on therapy longer because switching barriers exist (clinical stability, switching costs, patient adherence patterns).
• Financial outcome: slower revenue decline than the generic and guideline headwind would suggest.

Scenario B: Rapid payer shift

• Formularies move quickly to preferred INSTI regimens and reduce reimbursement tier positioning.
• Financial outcome: faster decline in both price and volume.

Scenario C: Procurement-led substitution

• In procurement-heavy geographies, buyers shift to lowest-cost generic options and alternative FDCs.
• Financial outcome: steep price erosion with limited volume offset.

Key Takeaways

• The emtricitabine / rilpivirine hydrochloride / tenofovir disoproxil fumarate FDC is a late-life HIV franchise line exposed to generic compression and guideline/payer migration toward INSTI-based regimens.
• Financial trajectory is most likely to follow a late-life stability turning into decline, driven by reduced new starts and continued switching out, partially offset by stable patient retention.
• The decision-critical drivers are net price trend, formulary tier status, generic and alternative regimen penetration, and claims-based switching rates.

FAQs

1. Is the regimen primarily affected by genericization of components or by brand-specific protection?
   Both. Component-level generic pressure and regimen switching reduce the brand premium, even when exact FDC protection varies by market.

2. What is the biggest driver of declining growth for older NNRTI-based FDCs?
   Payer and guideline preference shift toward INSTI-based regimens that are favored for new prescribing and, increasingly, for switches.

3. Why can volumes fall slower than revenue?
   Brand premium and contract pricing typically compress faster once generics and alternative regimens gain access, while continuation patients can persist longer.

4. What data sources best validate the trajectory?
   Company financial segment lines for HIV brands, prescription/claims time series, formulary status changes, and patent/generic calendars by major geography.

5. What is the main downside risk for remaining users?
   Abrupt formulary or procurement changes that reduce reimbursement or encourage switches, accelerating both price and volume erosion.

References

[1] FDA label database (Complera: emtricitabine, rilpivirine, and tenofovir disoproxil fumarate).
[2] EMA product information for rilpivirine/emtricitabine/tenofovir disoproxil fumarate (where applicable).
[3] Company annual reports and 10-K/20-F filings for HIV franchise revenue disclosures (product line reporting).
[4] Published patent and regulatory exclusivity databases (market-by-market expiry and generic entry timelines).
[5] Peer-reviewed and guideline literature on HIV regimen sequencing and ART class preference shifts (INSTI adoption).